Xenobiotic Laboratories
Xenobiotic Laboratories is recorded as a service provider in 13 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 13 of 13 trials · Latest update first
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects with BRAF-V600 Mutant Solid Tumors.
Sponsor C4 Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The Phase 2 dose-expansion phase was not initiated.
- A 12 April 2023 protocol amendment revised prior-anticancer-therapy eligibility from requiring BRAFi-naive participants to requiring prior BRAFi treatment when appropriate.
- A 6 February 2024 protocol amendment added CFT1946 plus cetuximab arms for BRAF V600-mutant colorectal cancer and updated enrollment stopping rules and eligibility criteria.
These findings describe the trial, not the service provider’s performance or responsibility.
KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
An International, Phase 3, Open-label, Randomized Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
MASTER PROTOCOL: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects with Biliary Atresia, Post-hepatoportoenterostomy
Sponsor Intercept Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Sponsor Beigene Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued treatment with everolimus after completion of Study CRAD001M2304 (EXIST-3)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Xenobiotic Laboratories?
The 2026-10-09 snapshot links Xenobiotic Laboratories to 13 distinct CTIS trials. Recorded services include Laboratory services, Bioanalytical services - Human plasma analysis (Dose Confirmation and Dose Optimization Part A Only), JDQ443 PK, Cetuximab PK, and ADA analysis, Pharmacokinetic bioanalysis, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Xenobiotic Laboratories?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Respiratory, Dermatology, Endocrinology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Xenobiotic Laboratories conducted?
The linked trials record locations in 16 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Xenobiotic Laboratories delivered services.
What can this page tell me about Xenobiotic Laboratories's trial experience?
Browse 13 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Xenobiotic Laboratories. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Xenobiotic Laboratories Inc.